{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:16:10Z","timestamp":1793769370117,"version":"4.6.1"},"reference-count":477,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody\u2013drug conjugates will be reviewed, as well as the current challenges and future directions for research.<\/jats:p>","DOI":"10.1093\/neuonc\/noaf177","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:31:04Z","timestamp":1753183864000},"page":"2751-2788","source":"Crossref","is-referenced-by-count":95,"title":["Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions"],"prefix":"10.1093","volume":"27","author":[{"given":"Patrick Y","family":"Wen","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Q","family":"Lee","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-7799","authenticated-orcid":false,"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[{"name":"Service de Neuro-oncologie, Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-9849","authenticated-orcid":false,"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[{"name":"The Preston Robert Tisch Brain Tumor Center, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaquat","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Dana-Farber Cancer Institute and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University and German Cancer Research Center, DKTK , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Stanford University , Stanford, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-6104","authenticated-orcid":false,"given":"Frank","family":"Winkler","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases , Heidelberg ,","place":["Germany"]},{"name":"German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]},{"name":"Department of Neurology, Heidelberg Medical Faculty of Heidelberg University, Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Horbinski","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-0436","authenticated-orcid":false,"given":"Roel G W","family":"Verhaak","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale School of Medicine , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Neuroradiology, Department of Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Baptist Health Miami Cancer Institute, Florida International University , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, Ludwig Maximilians University Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1756-423X","authenticated-orcid":false,"given":"Joerg-Christian","family":"Tonn","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery Klinikum Ludwig Maximilians University Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-2502","authenticated-orcid":false,"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, University of Virginia School of Medicine , Charlottesville, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-9304","authenticated-orcid":false,"given":"Jill S","family":"Barnholtz-Sloan","sequence":"additional","affiliation":[{"name":"Center for Biomedical Informatics and Information Technology and Division of Cancer Epidemiology and Genetics, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Ostrom","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D","family":"Aldape","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit S","family":"Bindra","sequence":"additional","affiliation":[{"name":"Departments of Therapeutic Radiology, Pathology, and Neurosugery, Yale Medical School , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Antonio","family":"Chiocca","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Mass General Brigham , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-7483","authenticated-orcid":false,"given":"Timothy F","family":"Cloughesy","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"DeGroot","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-9529","authenticated-orcid":false,"given":"Pim","family":"French","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC Cancer Institute , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-786X","authenticated-orcid":false,"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-1796","authenticated-orcid":false,"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[{"name":"Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) ,","place":["Germany"]},{"name":"Insitute of Neuroscience and Medicine (INM-3), Research Center Juelich , Juelich ,","place":["Germany"]},{"name":"Department of Neurology, Faculty of Medicine and University Hospital Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Gilbert","sequence":"additional","affiliation":[{"name":"National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika E","family":"Hegi","sequence":"additional","affiliation":[{"name":"Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B","family":"Lassman","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, and Herbert Irving Comprehensive Cancer Center , NewYork-Presbyterian, New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, and Brain Tumor Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh P","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Florida International University, Baptist Health, Miami Cancer Institute , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-8149","authenticated-orcid":false,"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza and IRCCS Neuromed , Pozzilli ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-214X","authenticated-orcid":false,"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-8476","authenticated-orcid":false,"given":"Marc","family":"Sanson","sequence":"additional","affiliation":[{"name":"Service de Neuro-oncologie, Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J B","family":"Taphoorn, Andreas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leiden University Medical Center ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"von Deimling, Tobias","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Heidelberg, and CCU Neuropathology, German Cancer Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[{"name":"Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6674-0157","authenticated-orcid":false,"given":"David A","family":"Reardon","sequence":"additional","affiliation":[{"name":"Department of Neurologic Surgery, Mayo Clinic College of Medicine and Science , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Chang","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C","family":"Short","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Department of Oncology, St James\u2019s University Hospital and University of Leeds , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC Cancer Institute , Rotterdam ,","place":["The Netherlands"]},{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"Supplement_6","key":"2026092211273527900_CIT0001","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"issue":"8","key":"2026092211273527900_CIT0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"Supplement_3","key":"2026092211273527900_CIT0003","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noae047","article-title":"CBTRUS statistical report: American Brain Tumor Association & NCI neuro-oncology branch adolescent and young adult primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"issue":"11","key":"2026092211273527900_CIT0004","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/neuonc\/nox091","article-title":"Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007","volume":"19","author":"Leece","year":"2017","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/neuonc\/noz203","article-title":"Glioblastoma multiforme incidence in Canada and the US in comparison with England 1995-2015","volume":"22","author":"Davis","year":"2019","journal-title":"Neuro Oncol"},{"key":"2026092211273527900_CIT0006","first-page":"7910754","article-title":"Brain tumours: rise in glioblastoma multiforme incidence in England 1995-2015 suggests an adverse environmental or lifestyle factor","volume":"2018","author":"Philips","year":"2018","journal-title":"J Environ Public Health"},{"issue":"8","key":"2026092211273527900_CIT0007","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/neuonc\/noab076","article-title":"The incidence of major subtypes of primary brain tumors in adults in England 1995-2017","volume":"23","author":"Wanis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"11","key":"2026092211273527900_CIT0008","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/neuonc\/noz123","article-title":"Risk factors for childhood and adult primary brain tumors","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"issue":"6","key":"2026092211273527900_CIT0009","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/all.15994","article-title":"AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper","volume":"79","author":"Turner","year":"2024","journal-title":"Allergy."},{"key":"2026092211273527900_CIT0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000464374","article-title":"Epidemiology of intracranial gliomas","volume":"30","author":"Ostrom","year":"2018","journal-title":"Prog Neurol Surg."},{"issue":"1","key":"2026092211273527900_CIT0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00381-013-2309-z","article-title":"Familial syndromes associated with intracranial tumours: a review","volume":"30","author":"Ranger","year":"2014","journal-title":"Child's Nerv Syst"},{"issue":"1","key":"2026092211273527900_CIT0012","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1148\/rg.2017160057","article-title":"Genetic syndromes associated with central nervous system tumors","volume":"37","author":"Vijapura","year":"2017","journal-title":"Radiographics"},{"issue":"18","key":"2026092211273527900_CIT0013","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-19-0032","article-title":"Genomic correlates of disease progression and treatment response in prospectively characterized gliomas","volume":"25","author":"Jonsson","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2026092211273527900_CIT0014","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ng.3823","article-title":"Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors","volume":"49","author":"Melin","year":"2017","journal-title":"Nat Genet."},{"issue":"5","key":"2026092211273527900_CIT0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00401-018-1825-z","article-title":"Diffuse gliomas classified by 1p\/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci","volume":"135","author":"Labreche","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2026092211273527900_CIT0016","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.2016.354","article-title":"Cell of origin of glioma: biological and clinical implications","volume":"115","author":"Alcantara Llaguno","year":"2016","journal-title":"Br J Cancer."},{"issue":"1","key":"2026092211273527900_CIT0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"issue":"3","key":"2026092211273527900_CIT0018","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2022.10.010","article-title":"Neuronal and tumourigenic boundaries of glioblastoma plasticity","volume":"9","author":"De Silva","year":"2023","journal-title":"Trends Cancer"},{"issue":"7","key":"2026092211273527900_CIT0019","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","article-title":"Genetic and molecular epidemiology of adult diffuse glioma","volume":"15","author":"Molinaro","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"5","key":"2026092211273527900_CIT0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ccell.2020.04.001","article-title":"The glioma stem cell model in the era of single-cell genomics","volume":"37","author":"Suva","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2026092211273527900_CIT0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat Rev Dis Primers."},{"issue":"2","key":"2026092211273527900_CIT0022","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"3","key":"2026092211273527900_CIT0023","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell."},{"issue":"4","key":"2026092211273527900_CIT0024","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","article-title":"Proteogenomic and metabolomic characterization of human glioblastoma","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"2026092211273527900_CIT0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"5897","key":"2026092211273527900_CIT0026","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science."},{"issue":"5","key":"2026092211273527900_CIT0027","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41588-018-0105-0","article-title":"Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma","volume":"50","author":"deCarvalho","year":"2018","journal-title":"Nat Genet."},{"issue":"7643","key":"2026092211273527900_CIT0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature21356","article-title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","volume":"543","author":"Turner","year":"2017","journal-title":"Nature."},{"issue":"10","key":"2026092211273527900_CIT0029","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7785","key":"2026092211273527900_CIT0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature."},{"issue":"7","key":"2026092211273527900_CIT0031","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat Genet."},{"issue":"2","key":"2026092211273527900_CIT0032","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","article-title":"Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective","volume":"187","author":"Mathur","year":"2024","journal-title":"Cell."},{"issue":"3","key":"2026092211273527900_CIT0033","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res."},{"issue":"3","key":"2026092211273527900_CIT0034","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2015.07.013","article-title":"Spatiotemporal evolution of the primary glioblastoma genome","volume":"28","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"2026092211273527900_CIT0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.19.00367","article-title":"Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study","volume":"38","author":"Draaisma","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2026092211273527900_CIT0036","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ccell.2019.02.007","article-title":"Evolutionary trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis","volume":"35","author":"Korber","year":"2019","journal-title":"Cancer Cell"},{"issue":"7","key":"2026092211273527900_CIT0037","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41588-021-00874-3","article-title":"Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer","volume":"53","author":"Kocakavuk","year":"2021","journal-title":"Nat Genet."},{"issue":"7804","key":"2026092211273527900_CIT0038","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature."},{"issue":"5","key":"2026092211273527900_CIT0039","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ejca.2013.12.005","article-title":"Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium","volume":"50","author":"Bakry","year":"2014","journal-title":"Eur J Cancer."},{"issue":"12","key":"2026092211273527900_CIT0040","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41576-022-00521-5","article-title":"Extrachromosomal DNA amplifications in cancer","volume":"23","author":"Yi","year":"2022","journal-title":"Nat Rev Genet."},{"issue":"2","key":"2026092211273527900_CIT0041","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2159-8290.CD-21-1376","article-title":"Live-cell imaging shows uneven segregation of extrachromosomal DNA elements and transcriptionally active extrachromosomal DNA hubs in cancer","volume":"12","author":"Yi","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"2026092211273527900_CIT0042","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/neuonc\/noad197","article-title":"Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma","volume":"26","author":"Eckhardt","year":"2024","journal-title":"Neuro Oncol"},{"issue":"7697","key":"2026092211273527900_CIT0043","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"1","key":"2026092211273527900_CIT0044","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"2026092211273527900_CIT0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"2026092211273527900_CIT0046","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"key":"2026092211273527900_CIT0047","first-page":"7","article-title":"Heterogeneity of DNA methylation profiles and copy number","volume":"5","author":"Reuss","year":"2024","journal-title":"Free Neuropathol"},{"issue":"2","key":"2026092211273527900_CIT0048","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s43018-020-00159-4","article-title":"Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities","volume":"2","author":"Garofano","year":"2021","journal-title":"Nat Cancer"},{"issue":"2","key":"2026092211273527900_CIT0049","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s43018-022-00510-x","article-title":"Integrative multi-omics networks identify PKCdelta and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy","volume":"4","author":"Migliozzi","year":"2023","journal-title":"Nat Cancer"},{"issue":"10","key":"2026092211273527900_CIT0050","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/s41588-021-00927-7","article-title":"Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states","volume":"53","author":"Chaligne","year":"2021","journal-title":"Nat Genet."},{"issue":"10","key":"2026092211273527900_CIT0051","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41588-021-00926-8","article-title":"Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response","volume":"53","author":"Johnson","year":"2021","journal-title":"Nat Genet."},{"issue":"4","key":"2026092211273527900_CIT0052","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell."},{"issue":"12","key":"2026092211273527900_CIT0053","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","article-title":"Glioma progression is shaped by genetic evolution and microenvironment interactions","volume":"185","author":"Varn","year":"2022","journal-title":"Cell."},{"issue":"1","key":"2026092211273527900_CIT0054","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-020-17186-5","article-title":"Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy","volume":"11","author":"Couturier","year":"2020","journal-title":"Nat Commun."},{"issue":"1","key":"2026092211273527900_CIT0055","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat Commun."},{"issue":"12","key":"2026092211273527900_CIT0056","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/2159-8290.CD-19-0329","article-title":"The phenotypes of proliferating glioblastoma cells reside on a single axis of variation","volume":"9","author":"Wang","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"2026092211273527900_CIT0057","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet."},{"issue":"3","key":"2026092211273527900_CIT0058","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ccell.2015.07.012","article-title":"DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors","volume":"28","author":"Mazor","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"2026092211273527900_CIT0059","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","article-title":"Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics","volume":"57","author":"Spitzer","year":"2025","journal-title":"Nat Genet."},{"issue":"6","key":"2026092211273527900_CIT0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","article-title":"Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma","volume":"40","author":"Ravi","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"2026092211273527900_CIT0061","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"2026092211273527900_CIT0062","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ccell.2023.02.019","article-title":"Transcriptome analysis reveals tumor microenvironment changes in glioblastoma","volume":"41","author":"Hoogstrate","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2026092211273527900_CIT0063","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan","year":"2023","journal-title":"J Clin Invest."},{"issue":"10","key":"2026092211273527900_CIT0064","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell."},{"issue":"6","key":"2026092211273527900_CIT0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","article-title":"Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma","volume":"39","author":"Hara","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"2026092211273527900_CIT0066","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/2159-8290.CD-20-0219","article-title":"Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing","volume":"11","author":"Schmitt","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"2026092211273527900_CIT0067","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: state of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell."},{"issue":"1","key":"2026092211273527900_CIT0068","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/2159-8290.CD-24-0194","article-title":"Cancer neuroscience of brain tumors: from multicellular networks to neuroscience-instructed cancer therapies","volume":"15","author":"Venkataramani","year":"2025","journal-title":"Cancer Discov"},{"issue":"7673","key":"2026092211273527900_CIT0069","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature."},{"issue":"4","key":"2026092211273527900_CIT0070","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","article-title":"Neuronal activity promotes glioma growth through neuroligin-3 secretion","volume":"161","author":"Venkatesh","year":"2015","journal-title":"Cell."},{"issue":"7914","key":"2026092211273527900_CIT0071","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41586-022-04719-9","article-title":"Olfactory sensory experience regulates gliomagenesis via neuronal IGF1","volume":"606","author":"Chen","year":"2022","journal-title":"Nature."},{"issue":"7971","key":"2026092211273527900_CIT0072","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41586-023-06267-2","article-title":"Remote neuronal activity drives glioma progression through SEMA4F","volume":"619","author":"Huang-Hobbs","year":"2023","journal-title":"Nature."},{"issue":"7862","key":"2026092211273527900_CIT0073","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","article-title":"NF1 mutation drives neuronal activity-dependent initiation of optic glioma","volume":"594","author":"Pan","year":"2021","journal-title":"Nature."},{"issue":"1","key":"2026092211273527900_CIT0074","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/2159-8290.CD-21-0245","article-title":"Rates and patterns of clonal oncogenic mutations in the normal human brain","volume":"12","author":"Ganz","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"2026092211273527900_CIT0075","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/brain\/awac180","article-title":"Regional healthy brain activity, glioma occurrence and symptomatology","volume":"145","author":"Numan","year":"2022","journal-title":"Brain."},{"issue":"7775","key":"2026092211273527900_CIT0076","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature."},{"issue":"16","key":"2026092211273527900_CIT0077","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","article-title":"Glioblastoma hijacks neuronal mechanisms for brain invasion","volume":"185","author":"Venkataramani","year":"2022","journal-title":"Cell."},{"issue":"7775","key":"2026092211273527900_CIT0078","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature."},{"issue":"50","key":"2026092211273527900_CIT0079","doi-asserted-by":"crossref","first-page":"e2417420121","DOI":"10.1073\/pnas.2417420121","article-title":"Widespread neuroanatomical integration and distinct electrophysiological properties of glioma-innervating neurons","volume":"121","author":"Hsieh","year":"2024","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"2026092211273527900_CIT0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cell.2024.11.002","article-title":"Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing","volume":"188","author":"Tetzlaff","year":"2025","journal-title":"Cell."},{"issue":"8061","key":"2026092211273527900_CIT0081","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41586-025-08634-7","article-title":"Brain-wide neuronal circuit connectome of human glioblastoma","volume":"641","author":"Sun","year":"2025","journal-title":"Nature."},{"issue":"6","key":"2026092211273527900_CIT0082","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/s41591-024-02969-w","article-title":"A prognostic neural epigenetic signature in high-grade glioma","volume":"30","author":"Drexler","year":"2024","journal-title":"Nat Med."},{"issue":"7580","key":"2026092211273527900_CIT0083","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature16071","article-title":"Brain tumour cells interconnect to a functional and resistant network","volume":"528","author":"Osswald","year":"2015","journal-title":"Nature."},{"issue":"1","key":"2026092211273527900_CIT0084","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41556-019-0443-x","article-title":"p120-catenin-dependent collective brain infiltration by glioma cell networks","volume":"22","author":"Gritsenko","year":"2020","journal-title":"Nat Cell Biol."},{"issue":"10","key":"2026092211273527900_CIT0085","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/neuonc\/nox070","article-title":"Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas","volume":"19","author":"Weil","year":"2017","journal-title":"Neuro Oncol"},{"issue":"7942","key":"2026092211273527900_CIT0086","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41586-022-05520-4","article-title":"Autonomous rhythmic activity in glioma networks drives brain tumour growth","volume":"613","author":"Hausmann","year":"2023","journal-title":"Nature."},{"issue":"1","key":"2026092211273527900_CIT0087","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41467-024-45067-8","article-title":"A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1","volume":"15","author":"Hai","year":"2024","journal-title":"Nat Commun."},{"issue":"7793","key":"2026092211273527900_CIT0088","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-020-1952-2","article-title":"PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis","volume":"578","author":"Yu","year":"2020","journal-title":"Nature."},{"issue":"7961","key":"2026092211273527900_CIT0089","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","article-title":"Glioblastoma remodelling of human neural circuits decreases survival","volume":"617","author":"Krishna","year":"2023","journal-title":"Nature."},{"issue":"8","key":"2026092211273527900_CIT0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026092211273527900_CIT0091","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/neuonc\/noac089","article-title":"Prospective genomically guided identification of \u201cearly\/evolving\u201d and \u201cundersampled\u201d IDH-wildtype glioblastoma leads to improved clinical outcomes","volume":"24","author":"Zhang","year":"2022","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026092211273527900_CIT0092","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoncol.2024.5506","article-title":"Molecular testing for the world health organization classification of central nervous system tumors: a review","volume":"11","author":"Horbinski","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10","key":"2026092211273527900_CIT0093","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/neuonc\/noad100","article-title":"Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline","volume":"25","author":"Sahm","year":"2023","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0094","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/neuonc\/noae213","article-title":"Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1","volume":"27","author":"van den Bent","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40478-021-01308-1","article-title":"Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival","volume":"10","author":"Ebrahimi","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"2026092211273527900_CIT0096","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00401-022-02404-9","article-title":"High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13","volume":"143","author":"Pratt","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2026092211273527900_CIT0097","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","article-title":"Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations","volume":"136","author":"Reinhardt","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2026092211273527900_CIT0098","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s40478-023-01680-0","article-title":"Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results","volume":"11","author":"McCord","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"2026092211273527900_CIT0099","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/neuonc\/noaa258","article-title":"IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification","volume":"23","author":"Berzero","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00401-021-02337-9","article-title":"TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma","volume":"142","author":"Fujimoto","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2026092211273527900_CIT0101","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","article-title":"Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma","volume":"136","author":"Stichel","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"20","key":"2026092211273527900_CIT0102","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"2026092211273527900_CIT0103","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"32","key":"2026092211273527900_CIT0104","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol."},{"issue":"10","key":"2026092211273527900_CIT0105","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"7","key":"2026092211273527900_CIT0106","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol."},{"issue":"11","key":"2026092211273527900_CIT0107","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"2026092211273527900_CIT0108","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ane.12401","article-title":"Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis","volume":"132","author":"Chen","year":"2015","journal-title":"Acta Neurol Scand."},{"issue":"3","key":"2026092211273527900_CIT0109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/neuonc\/noab231","article-title":"The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis","volume":"24","author":"Hoogstrate","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/neuonc\/noae214","article-title":"Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses","volume":"27","author":"Lucas","year":"2025","journal-title":"Neuro Oncol"},{"issue":"9","key":"2026092211273527900_CIT0111","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstrom","year":"2012","journal-title":"Lancet Oncol."},{"issue":"38","key":"2026092211273527900_CIT0112","doi-asserted-by":"crossref","first-page":"61916","DOI":"10.18632\/oncotarget.11322","article-title":"Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial","volume":"7","author":"Quillien","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"2026092211273527900_CIT0113","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-18-3181","article-title":"MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials","volume":"25","author":"Hegi","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2026092211273527900_CIT0114","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","article-title":"No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients","volume":"26","author":"Hegi","year":"2024","journal-title":"Neuro Oncol"},{"issue":"14","key":"2026092211273527900_CIT0115","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","article-title":"Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial","volume":"34","author":"Herrlinger","year":"2016","journal-title":"J Clin Oncol."},{"issue":"19","key":"2026092211273527900_CIT0116","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2026092211273527900_CIT0117","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/1078-0432.CCR-21-4283","article-title":"Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the EORTC randomized phase III CATNON trial","volume":"28","author":"Tesileanu","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"224","key":"2026092211273527900_CIT0118","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med."},{"issue":"7741","key":"2026092211273527900_CIT0119","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature."},{"key":"2026092211273527900_CIT0120","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun."},{"issue":"7984","key":"2026092211273527900_CIT0121","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41586-023-06615-2","article-title":"Ultra-fast deep-learned CNS tumour classification during surgery","volume":"622","author":"Vermeulen","year":"2023","journal-title":"Nature."},{"issue":"7","key":"2026092211273527900_CIT0122","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-020-0932-2","article-title":"Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes","volume":"26","author":"Nassiri","year":"2020","journal-title":"Nat Med."},{"issue":"9","key":"2026092211273527900_CIT0123","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/neuonc\/noab023","article-title":"A serum-based DNA methylation assay provides accurate detection of glioma","volume":"23","author":"Sabedot","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2026092211273527900_CIT0124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2967\/jnumed.122.264859","article-title":"Amino acid PET in neurooncology","volume":"64","author":"Galldiks","year":"2023","journal-title":"J Nucl Med."},{"issue":"6","key":"2026092211273527900_CIT0125","doi-asserted-by":"crossref","first-page":"e230078","DOI":"10.1148\/rycan.230078","article-title":"Current state of functional MRI in the presurgical planning of brain tumors","volume":"5","author":"Lakhani","year":"2023","journal-title":"Radiol Imaging Cancer"},{"issue":"5","key":"2026092211273527900_CIT0126","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3174\/ajnr.A6025","article-title":"Non-contrast-enhancing tumor: a new frontier in glioblastoma research","volume":"40","author":"Lasocki","year":"2019","journal-title":"AJNR Am J Neuroradiol."},{"issue":"5","key":"2026092211273527900_CIT0127","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026092211273527900_CIT0128","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/neuonc\/now036","article-title":"Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients","volume":"18","author":"Cordova","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026092211273527900_CIT0129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ijrobp.2015.02.058","article-title":"Hypercellularity components of glioblastoma identified by high b-value diffusion-weighted imaging","volume":"92","author":"Pramanik","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"2026092211273527900_CIT0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/neuonc\/noae049","article-title":"Challenges, limitations and Pitfalls of PET and advanced MRI in patients with brain tumors - a report of the PET\/RANO Group","volume":"26","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol"},{"issue":"6","key":"2026092211273527900_CIT0131","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/neuonc\/noab013","article-title":"Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET\/RANO group","volume":"23","author":"Galldiks","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2026092211273527900_CIT0132","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/jpm14050538","article-title":"Preferred imaging for target volume delineation for radiotherapy of recurrent glioblastoma: a literature review of the available evidence","volume":"14","author":"Cuccia","year":"2024","journal-title":"J Pers Med"},{"issue":"12","key":"2026092211273527900_CIT0133","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S1470-2045(24)00585-0","article-title":"Short-course hypofractionated proton beam therapy, incorporating (18)F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial","volume":"25","author":"Vora","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026092211273527900_CIT0134","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/WCO.0000000000001212","article-title":"How to evaluate extent of resection in diffuse gliomas: from standards to new methods","volume":"36","author":"Teske","year":"2023","journal-title":"Curr Opin Neurol."},{"issue":"1","key":"2026092211273527900_CIT0135","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1038\/s41467-023-39731-8","article-title":"Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma","volume":"14","author":"Harat","year":"2023","journal-title":"Nat Commun."},{"issue":"11","key":"2026092211273527900_CIT0136","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S1470-2045(23)00453-9","article-title":"A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups","volume":"24","author":"Karschnia","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026092211273527900_CIT0137","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/neuonc\/noae208","article-title":"Measurable disease as baseline criterion for response assessment in glioblastoma: a comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments","volume":"27","author":"Muller","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0138","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s12885-016-2806-z","article-title":"Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10\/ARO 2013-1)","volume":"16","author":"Oehlke","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"2026092211273527900_CIT0139","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-023-04407-2","article-title":"The evolving role of reirradiation in the management of recurrent brain tumors","volume":"164","author":"De Pietro","year":"2023","journal-title":"J Neurooncol."},{"issue":"11","key":"2026092211273527900_CIT0140","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/neuonc\/noac131","article-title":"Investigational PET tracers in neuro-oncology-What\u2019s on the horizon? A report of the PET\/RANO group","volume":"24","author":"Galldiks","year":"2022","journal-title":"Neuro Oncol"},{"issue":"13","key":"2026092211273527900_CIT0141","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026092211273527900_CIT0142","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/neuonc\/nou129","article-title":"Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence","volume":"17","author":"Radbruch","year":"2015","journal-title":"Neuro Oncol"},{"issue":"17","key":"2026092211273527900_CIT0143","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.22.01579","article-title":"Evaluation of standard response assessment in neuro-oncology, modified response assessment in neuro-oncology, and immunotherapy response assessment in neuro-oncology in newly diagnosed and recurrent glioblastoma","volume":"41","author":"Youssef","year":"2023","journal-title":"J Clin Oncol."},{"issue":"5","key":"2026092211273527900_CIT0144","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol."},{"issue":"10","key":"2026092211273527900_CIT0145","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/neuonc\/now091","article-title":"Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro. Oncol"},{"issue":"1","key":"2026092211273527900_CIT0146","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11060-006-9241-y","article-title":"Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma","volume":"82","author":"Chamberlain","year":"2007","journal-title":"J Neurooncol."},{"issue":"2","key":"2026092211273527900_CIT0147","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cncr.23562","article-title":"Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide","volume":"113","author":"Taal","year":"2008","journal-title":"Cancer."},{"issue":"4","key":"2026092211273527900_CIT0148","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/neuonc\/noz233","article-title":"Toward a standard pathological and molecular characterization of recurrent glioma in adults: a response assessment in neuro-oncology effort","volume":"22","author":"Haider","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-023-04528-8","article-title":"Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis","volume":"166","author":"Dagher","year":"2024","journal-title":"J Neurooncol."},{"issue":"5","key":"2026092211273527900_CIT0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00259-014-2959-4","article-title":"Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET","volume":"42","author":"Galldiks","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2026092211273527900_CIT0151","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp-2017-317155","article-title":"O-(2-((18)F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma","volume":"90","author":"Mihovilovic","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"9","key":"2026092211273527900_CIT0152","first-page":"1293","article-title":"The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma","volume":"17","author":"Galldiks","year":"2015","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026092211273527900_CIT0153","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/neuonc\/not166","article-title":"Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET\/CT for recurrence detection in glioblastoma patients","volume":"16","author":"Herrmann","year":"2014","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026092211273527900_CIT0154","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/neuonc\/noz166","article-title":"Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET)","volume":"21","author":"Bashir","year":"2019","journal-title":"Neuro Oncol"},{"issue":"13","key":"2026092211273527900_CIT0155","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1158\/1078-0432.CCR-21-0471","article-title":"Diagnosis of pseudoprogression following lomustine-temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET-PET","volume":"27","author":"Werner","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2026092211273527900_CIT0156","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2967\/jnumed.122.264812","article-title":"Distinguishing progression from pseudoprogression in glioblastoma using (18)F-Fluciclovine PET","volume":"64","author":"Nabavizadeh","year":"2023","journal-title":"J Nucl Med."},{"issue":"14","key":"2026092211273527900_CIT0157","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3390\/cancers14143336","article-title":"Two decades of brain tumour imaging with O-(2-[(18)F]fluoroethyl)-L-tyrosine PET: the forschungszentrum julich experience","volume":"14","author":"Heinzel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026092211273527900_CIT0158","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S1470-2045(24)00316-4","article-title":"Artificial intelligence for response assessment in neuro oncology (AI-RANO), part 1: review of current advancements","volume":"25","author":"Villanueva-Meyer","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"2026092211273527900_CIT0159","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/S1470-2045(24)00315-2","article-title":"Artificial intelligence for response assessment in neuro oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice","volume":"25","author":"Bakas","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"2026092211273527900_CIT0160","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"15","key":"2026092211273527900_CIT0161","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026092211273527900_CIT0162","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"33","key":"2026092211273527900_CIT0163","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol."},{"issue":"5","key":"2026092211273527900_CIT0164","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/neuonc\/nos070","article-title":"Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria","volume":"14","author":"Gallego Perez-Larraya","year":"2012","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0165","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026092211273527900_CIT0166","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2020.11.003","article-title":"Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up","volume":"32","author":"Roth","year":"2021","journal-title":"Ann Oncol."},{"issue":"3","key":"2026092211273527900_CIT0167","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"Koekkoek","year":"2023","journal-title":"Neuro Oncol"},{"issue":"11","key":"2026092211273527900_CIT0168","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11910-023-01301-2","article-title":"Palliative care in neuro-oncology: an update","volume":"23","author":"Rhee","year":"2023","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"1","key":"2026092211273527900_CIT0169","doi-asserted-by":"crossref","first-page":"e207902","DOI":"10.1212\/WNL.0000000000207902","article-title":"Characteristics and prognosis of tumor-related epilepsy during tumor evolution in patients with IDH wild-type glioblastoma","volume":"102","author":"Pallud","year":"2024","journal-title":"Neurology."},{"issue":"1","key":"2026092211273527900_CIT0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/noad154","article-title":"Brain tumor-related epilepsy management: a Society for Neuro-oncology (SNO) consensus review on current management","volume":"26","author":"Avila","year":"2024","journal-title":"Neuro Oncol"},{"issue":"11","key":"2026092211273527900_CIT0171","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","article-title":"SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors","volume":"23","author":"Walbert","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7","key":"2026092211273527900_CIT0172","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026092211273527900_CIT0173","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-021-03940-2","article-title":"The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis","volume":"156","author":"Chen","year":"2022","journal-title":"J Neurooncol."},{"issue":"7","key":"2026092211273527900_CIT0174","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1212\/WNL.0000000000011414","article-title":"Risk of venous thromboembolism in grade II-IV gliomas as a function of molecular subtype","volume":"96","author":"Diaz","year":"2021","journal-title":"Neurology."},{"issue":"8","key":"2026092211273527900_CIT0175","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/neuonc\/noad059","article-title":"Epidemiology, biology, and management of venous thromboembolism in gliomas: an interdisciplinary review","volume":"25","author":"Jo","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026092211273527900_CIT0176","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review","volume":"89","author":"Marras","year":"2000","journal-title":"Cancer."},{"issue":"3","key":"2026092211273527900_CIT0177","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/neuonc\/noab198","article-title":"Management of venous thromboembolism in high-grade glioma: does low molecular weight heparin increase intracranial bleeding risk","volume":"24","author":"Jo","year":"2022","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026092211273527900_CIT0178","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study","volume":"24","author":"Reed-Guy","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2026092211273527900_CIT0179","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/onco.13698","article-title":"Safety of direct oral anticoagulants in central nervous system malignancies","volume":"26","author":"Swartz","year":"2021","journal-title":"Oncologist."},{"issue":"1","key":"2026092211273527900_CIT0180","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10143-021-01539-9","article-title":"Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma","volume":"45","author":"Dubinski","year":"2022","journal-title":"Neurosurg Rev."},{"issue":"4","key":"2026092211273527900_CIT0181","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/neuonc\/nou304","article-title":"Medical management of brain tumors and the sequelae of treatment","volume":"17","author":"Schiff","year":"2015","journal-title":"Neuro Oncol"},{"issue":"9","key":"2026092211273527900_CIT0182","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"6","key":"2026092211273527900_CIT0183","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"2026092211273527900_CIT0184","doi-asserted-by":"crossref","first-page":"E607","DOI":"10.1093\/neuros\/nyz186","article-title":"Letter: when less is more: dexamethasone dosing for brain tumors","volume":"85","author":"Lim-Fat","year":"2019","journal-title":"Neurosurgery."},{"issue":"4","key":"2026092211273527900_CIT0185","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.44.4.675","article-title":"Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16\u00a0mg per day","volume":"44","author":"Vecht","year":"1994","journal-title":"Neurology."},{"issue":"1","key":"2026092211273527900_CIT0186","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11910-017-0713-6","article-title":"Clinical relevance of steroid use in neuro-oncology","volume":"17","author":"Ly","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"9","key":"2026092211273527900_CIT0187","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/neuonc\/now167","article-title":"Corticosteroids for peritumoral edema: time to overcome our addiction","volume":"18","author":"Lee","year":"2016","journal-title":"Neuro Oncol."},{"issue":"Pt 5","key":"2026092211273527900_CIT0188","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain."},{"issue":"4","key":"2026092211273527900_CIT0189","first-page":"310","article-title":"Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101","volume":"9","author":"Caramanna","year":"2022","journal-title":"Neurooncol. Pract.."},{"issue":"1","key":"2026092211273527900_CIT0190","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026092211273527900_CIT0191","doi-asserted-by":"crossref","first-page":"e003368","DOI":"10.1136\/jitc-2021-003368","article-title":"Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models","volume":"10","author":"Koch","year":"2022","journal-title":"J ImmunoTher Cancer."},{"issue":"3","key":"2026092211273527900_CIT0192","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11060-022-04109-1","article-title":"Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy","volume":"159","author":"Climans","year":"2022","journal-title":"J Neurooncol."},{"issue":"30","key":"2026092211273527900_CIT0193","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol."},{"issue":"12","key":"2026092211273527900_CIT0194","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2026092211273527900_CIT0195","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/neuonc\/nov084","article-title":"Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue","volume":"17","author":"Page","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0196","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jamaoncol.2021.5948","article-title":"Efficacy of treatment with armodafinil for cancer-related fatigue in patients with high-grade glioma: a phase 3 randomized clinical trial","volume":"8","author":"Porter","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026092211273527900_CIT0197","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/neuonc\/nov166","article-title":"The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026092211273527900_CIT0198","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-014-1574-3","article-title":"Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients","volume":"120","author":"Peters","year":"2014","journal-title":"J Neurooncol."},{"key":"2026092211273527900_CIT0199","article-title":"Clinical practice guidelines in oncology: cancer-related fatigue, version 2.2024","volume-title":"Plymouth Meeting","author":"National Comprehensive Cancer Network (NCCN)","year":"2024"},{"issue":"9","key":"2026092211273527900_CIT0200","first-page":"CD011376","article-title":"Interventions for the management of fatigue in adults with a primary brain tumour","volume":"9","author":"Day","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"2026092211273527900_CIT0201","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/neuonc\/now007","article-title":"A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy","volume":"18","author":"Lee","year":"2016","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026092211273527900_CIT0202","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/neuonc\/not102","article-title":"The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial","volume":"15","author":"Boele","year":"2013","journal-title":"Neuro Oncol"},{"issue":"5","key":"2026092211273527900_CIT0203","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.ijrobp.2007.05.076","article-title":"A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy","volume":"69","author":"Butler","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2026092211273527900_CIT0204","first-page":"vdz043","article-title":"A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA)","volume":"1","author":"Laigle-Donadey","year":"2019","journal-title":"Neurooncol. Adv.."},{"issue":"1","key":"2026092211273527900_CIT0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40880-019-0390-8","article-title":"Effects of two types of exercise training on psychological well-being, sleep, quality of life and physical fitness in patients with high-grade glioma (WHO III and IV): study protocol for a randomized controlled trial","volume":"39","author":"Cordier","year":"2019","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"2026092211273527900_CIT0206","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s13063-022-06485-5","article-title":"Reducing severe fatigue in patients with diffuse glioma: a study protocol for an RCT on the effect of blended cognitive behavioural therapy","volume":"23","author":"Rottgering","year":"2022","journal-title":"Trials"},{"issue":"Suppl 2","key":"2026092211273527900_CIT0207","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/nov267","article-title":"Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"2026092211273527900_CIT0208","first-page":"89","article-title":"Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma","volume":"10","author":"Sekely","year":"2023","journal-title":"Neurooncol. Pract.."},{"issue":"15","key":"2026092211273527900_CIT0209","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2014.58.4508","article-title":"Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial","volume":"33","author":"Rapp","year":"2015","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026092211273527900_CIT0210","first-page":"114","article-title":"Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: results of the WFU CCOP research base protocol 91105","volume":"5","author":"Naughton","year":"2018","journal-title":"Neurooncol. Pract.."},{"issue":"9","key":"2026092211273527900_CIT0211","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/neuonc\/noad074","article-title":"Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0212","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/neuonc\/noz178","article-title":"A pilot randomized controlled trial of exercise to improve cognitive performance in patients with stable glioma: a proof of concept","volume":"22","author":"Gehring","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026092211273527900_CIT0213","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-019-03130-1","article-title":"Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial","volume":"142","author":"Richard","year":"2019","journal-title":"J Neurooncol."},{"issue":"1","key":"2026092211273527900_CIT0214","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40170-020-00230-9","article-title":"Treatment of glioblastoma multiforme with \u201cclassic\u201d 4:1 ketogenic diet total meal replacement","volume":"8","author":"Klein","year":"2020","journal-title":"Cancer Metab"},{"issue":"1","key":"2026092211273527900_CIT0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11060-020-03417-8","article-title":"Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study","volume":"147","author":"Martin-McGill","year":"2020","journal-title":"J Neurooncol."},{"issue":"4","key":"2026092211273527900_CIT0216","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijrobp.2020.06.021","article-title":"ERGO2: a prospective, randomized trial of calorie-restricted ketogenic diet and fasting in addition to reirradiation for malignant glioma","volume":"108","author":"Voss","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"9","key":"2026092211273527900_CIT0217","doi-asserted-by":"crossref","first-page":"e953","DOI":"10.1212\/WNL.0000000000012386","article-title":"Feasibility and biological activity of a ketogenic\/intermittent-fasting diet in patients with glioma","volume":"97","author":"Schreck","year":"2021","journal-title":"Neurology."},{"issue":"7","key":"2026092211273527900_CIT0218","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2008.19.1098","article-title":"Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma","volume":"27","author":"Derr","year":"2009","journal-title":"J Clin Oncol."},{"issue":"21","key":"2026092211273527900_CIT0219","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2011.34.9852","article-title":"Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma","volume":"29","author":"Ruden","year":"2011","journal-title":"J Clin Oncol."},{"issue":"3","key":"2026092211273527900_CIT0220","first-page":"249","article-title":"Lifestyle coaching is feasible in fatigued brain tumor patients: a phase I\/feasibility, multi-center, mixed-methods randomized controlled trial","volume":"10","author":"Rooney","year":"2023","journal-title":"Neurooncol. Pract.."},{"issue":"4","key":"2026092211273527900_CIT0221","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/neuonc\/noae231","article-title":"Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: a report of the RANO resect group","volume":"27","author":"Karschnia","year":"2024","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026092211273527900_CIT0222","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archneurol.2011.2910","article-title":"Addressing diffuse glioma as a systemic brain disease with single-cell analysis","volume":"69","author":"Sahm","year":"2012","journal-title":"Arch Neurol."},{"issue":"9","key":"2026092211273527900_CIT0223","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(24)00130-X","article-title":"The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group","volume":"25","author":"Karschnia","year":"2024","journal-title":"Lancet Oncol."},{"issue":"4","key":"2026092211273527900_CIT0224","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026092211273527900_CIT0225","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/neuonc\/noad160","article-title":"Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group","volume":"26","author":"Karschnia","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0226","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1227\/NEU.0b013e318223f5a7","article-title":"Application of novel response\/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group","volume":"70","author":"Vogelbaum","year":"2012","journal-title":"Neurosurgery."},{"issue":"6","key":"2026092211273527900_CIT0227","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(22)00213-3","article-title":"Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study","volume":"23","author":"Gerritsen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026092211273527900_CIT0228","first-page":"vdaa111","article-title":"Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Zhang","year":"2020","journal-title":"Neurooncol. Adv.."},{"issue":"2","key":"2026092211273527900_CIT0229","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-021-03901-9","article-title":"Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review","volume":"156","author":"Eatz","year":"2022","journal-title":"J Neurooncol."},{"key":"2026092211273527900_CIT0230","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jocn.2022.02.028","article-title":"Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for resection of high-grade gliomas: a systematic review and network meta-analysis","volume":"98","author":"Naik","year":"2022","journal-title":"J Clin Neurosci."},{"issue":"2","key":"2026092211273527900_CIT0231","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/brainsci13020216","article-title":"Maximal safe resection in glioblastoma surgery: a systematic review of advanced intraoperative image-guided techniques","volume":"13","author":"Bonosi","year":"2023","journal-title":"Brain Sci"},{"issue":"1","key":"2026092211273527900_CIT0232","first-page":"CD013630","article-title":"Intraoperative imaging technology to maximise extent of resection for glioma: a network meta-analysis","volume":"1","author":"Fountain","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"issue":"36","key":"2026092211273527900_CIT0233","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.22.01862","article-title":"Intraoperative MRI-guided resection is not superior to 5-aminolevulinic acid guidance in newly diagnosed glioblastoma: a prospective controlled multicenter clinical trial","volume":"41","author":"Roder","year":"2023","journal-title":"J Clin Oncol."},{"issue":"8045","key":"2026092211273527900_CIT0234","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-024-08169-3","article-title":"Foundation models for fast, label-free detection of glioma infiltration","volume":"637","author":"Kondepudi","year":"2025","journal-title":"Nature."},{"issue":"1","key":"2026092211273527900_CIT0235","first-page":"vdad126","article-title":"Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study","volume":"5","author":"Bjorland","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"1","key":"2026092211273527900_CIT0236","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00701-024-06090-2","article-title":"Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification","volume":"166","author":"Tropeano","year":"2024","journal-title":"Acta Neurochir (Wien)."},{"issue":"3","key":"2026092211273527900_CIT0237","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"8","key":"2026092211273527900_CIT0238","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00701-014-2073-1","article-title":"Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients","volume":"156","author":"Eigenbrod","year":"2014","journal-title":"Acta Neurochir (Wien)."},{"issue":"1","key":"2026092211273527900_CIT0239","first-page":"vdac040","article-title":"Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma","volume":"4","author":"de Groot","year":"2022","journal-title":"Neurooncol. Adv.."},{"key":"2026092211273527900_CIT0240","author":"National Comprehensive Cancer Network"},{"issue":"12","key":"2026092211273527900_CIT0241","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026092211273527900_CIT0242","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","article-title":"Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology\/RTOG","volume":"19","author":"Blumenthal","year":"2017","journal-title":"Neuro Oncol"},{"issue":"23","key":"2026092211273527900_CIT0243","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"issue":"11","key":"2026092211273527900_CIT0244","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","article-title":"Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma","volume":"17","author":"Hegi","year":"2015","journal-title":"Neuro Oncol"},{"issue":"10172","key":"2026092211273527900_CIT0245","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet."},{"issue":"8","key":"2026092211273527900_CIT0246","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"8","key":"2026092211273527900_CIT0247","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"issue":"3","key":"2026092211273527900_CIT0248","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"2026092211273527900_CIT0249","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2002.20.6.1635","article-title":"Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy","volume":"20","author":"Chan","year":"2002","journal-title":"J Clin Oncol."},{"issue":"6","key":"2026092211273527900_CIT0250","first-page":"279","article-title":"Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401\/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group","author":"Nelson","year":"1988","journal-title":"NCI Monogr"},{"issue":"10","key":"2026092211273527900_CIT0251","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4","key":"2026092211273527900_CIT0252","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.1991.396","article-title":"A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party","volume":"64","author":"Bleehen","year":"1991","journal-title":"Br J Cancer."},{"issue":"3","key":"2026092211273527900_CIT0253","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11060-024-04824-x","article-title":"Radiotherapeutic advances in the management of glioblastoma","volume":"170","author":"Gal","year":"2024","journal-title":"J Neurooncol."},{"key":"2026092211273527900_CIT0254","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol."},{"issue":"1","key":"2026092211273527900_CIT0255","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-019-03152-9","article-title":"NRG brain tumor specialists consensus guidelines for glioblastoma contouring","volume":"143","author":"Kruser","year":"2019","journal-title":"J Neurooncol."},{"issue":"8","key":"2026092211273527900_CIT0256","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/neuonc\/noaa019","article-title":"A phase I\/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes","volume":"22","author":"Azoulay","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0257","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.prro.2018.06.001","article-title":"Using smaller-than-standard radiation treatment margins does not change survival outcomes in patients with high-grade gliomas","volume":"9","author":"Guram","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"2026092211273527900_CIT0258","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1748-717X-9-130","article-title":"Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide","volume":"9","author":"Gebhardt","year":"2014","journal-title":"Radiat Oncol."},{"issue":"1","key":"2026092211273527900_CIT0259","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2009.10.048","article-title":"Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma","volume":"79","author":"McDonald","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12 Suppl 2","key":"2026092211273527900_CIT0260","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/neuonc\/noad258","article-title":"Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: a new future is on the horizon","volume":"26","author":"Tseng","year":"2024","journal-title":"Neuro Oncol."},{"issue":"5","key":"2026092211273527900_CIT0261","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial results of a phase 2 trial of (18)F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma","volume":"110","author":"Laack","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2026092211273527900_CIT0262","first-page":"vdac006","article-title":"A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma","volume":"4","author":"Ramesh","year":"2022","journal-title":"Neurooncol. Adv.."},{"issue":"3","key":"2026092211273527900_CIT0263","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2021.01.033","article-title":"A phase 2 study of dose-intensified chemoradiation using biologically based target volume definition in patients with newly diagnosed glioblastoma","volume":"110","author":"Kim","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2026092211273527900_CIT0264","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.radonc.2010.08.018","article-title":"Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues","volume":"97","author":"Amelio","year":"2010","journal-title":"Radiother Oncol."},{"issue":"2","key":"2026092211273527900_CIT0265","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026092211273527900_CIT0266","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0267","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00701-002-1030-6","article-title":"Debulking or biopsy of malignant glioma in elderly people - a randomised study","volume":"145","author":"Vuorinen","year":"2003","journal-title":"Acta Neurochir (Wien)."},{"issue":"5","key":"2026092211273527900_CIT0268","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3171\/2022.8.JNS221068","article-title":"Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d\u2019Expression Francaise (ANOCEF) trial","volume":"138","author":"Laigle-Donadey","year":"2023","journal-title":"J Neurosurg."},{"issue":"12","key":"2026092211273527900_CIT0269","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One."},{"issue":"2","key":"2026092211273527900_CIT0270","first-page":"132","article-title":"Glioblastoma in the oldest old: clinical characteristics, therapy, and outcome in patients aged 80 years and older","volume":"11","author":"Stadler","year":"2024","journal-title":"Neurooncol. Pract.."},{"issue":"26","key":"2026092211273527900_CIT0271","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol."},{"issue":"7","key":"2026092211273527900_CIT0272","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J Clin Oncol."},{"issue":"6","key":"2026092211273527900_CIT0273","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/neuonc\/noad002","article-title":"Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival","volume":"25","author":"Ellingson","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0274","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/noae209","article-title":"Point\/Counterpoint: the role of reirradiation in recurrent glioblastoma","volume":"27","author":"Rahman","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0275","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13063-024-08213-7","article-title":"Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study","volume":"25","author":"Preusser","year":"2024","journal-title":"Trials"},{"issue":"7","key":"2026092211273527900_CIT0276","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/neuonc\/not040","article-title":"Phase 2 study of dose-intense temozolomide in recurrent glioblastoma","volume":"15","author":"Norden","year":"2013","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026092211273527900_CIT0277","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","article-title":"Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study","volume":"28","author":"Perry","year":"2010","journal-title":"J Clin Oncol."},{"issue":"5","key":"2026092211273527900_CIT0278","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026092211273527900_CIT0279","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"11","key":"2026092211273527900_CIT0280","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"6","key":"2026092211273527900_CIT0281","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/annonc\/mdy106","article-title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","volume":"29","author":"Gramatzki","year":"2018","journal-title":"Ann Oncol."},{"issue":"7","key":"2026092211273527900_CIT0282","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026092211273527900_CIT0283","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026092211273527900_CIT0284","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026092211273527900_CIT0285","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026092211273527900_CIT0286","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase i dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"2026092211273527900_CIT0287","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"2026092211273527900_CIT0288","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro Oncol."},{"issue":"6","key":"2026092211273527900_CIT0289","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","article-title":"Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma","volume":"20","author":"Snuderl","year":"2011","journal-title":"Cancer Cell"},{"issue":"5848","key":"2026092211273527900_CIT0290","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science."},{"issue":"8","key":"2026092211273527900_CIT0291","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","article-title":"EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing","volume":"4","author":"Francis","year":"2014","journal-title":"Cancer Discov"},{"issue":"6166","key":"2026092211273527900_CIT0292","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science."},{"issue":"7","key":"2026092211273527900_CIT0293","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/neuonc\/noab282","article-title":"Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making","volume":"24","author":"Lim-Fat","year":"2022","journal-title":"Neuro Oncol"},{"issue":"6","key":"2026092211273527900_CIT0294","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/neuonc\/nox216","article-title":"Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study","volume":"20","author":"Pfaff","year":"2018","journal-title":"Neuro Oncol"},{"issue":"11","key":"2026092211273527900_CIT0295","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/1878-0261.12790","article-title":"Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility - a prospective, translational study","volume":"14","author":"Noroxe","year":"2020","journal-title":"Mol Oncol."},{"issue":"2","key":"2026092211273527900_CIT0296","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1078-0432.CCR-17-0963","article-title":"Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma","volume":"24","author":"Byron","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2026092211273527900_CIT0297","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/neuonc\/noac204","article-title":"EGFR, the Lazarus target for precision oncology in glioblastoma","volume":"24","author":"Lin","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7","key":"2026092211273527900_CIT0298","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann Oncol."},{"issue":"Suppl 8","key":"2026092211273527900_CIT0299","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/neuonc\/nou232","article-title":"Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges","volume":"16","author":"Reardon","year":"2014","journal-title":"Neuro Oncol."},{"issue":"16_suppl","key":"2026092211273527900_CIT0300","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1200\/JCO.2024.42.16_suppl.2068","article-title":"Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results","volume":"42","author":"Wen","year":"2024","journal-title":"J Clin Oncol."},{"issue":"Supplement_8","key":"2026092211273527900_CIT0301","doi-asserted-by":"crossref","first-page":"viii107","DOI":"10.1093\/neuonc\/noae165.0415","article-title":"CTNI-48. A phase 1 study of ERAS-801, a potent, selective, and central nervous system (CNS)-penetrant epidermal growth factor receptor (EGFR) inhibitor, for patients with recurrent glioblastoma multiforme (GBM)","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro-Oncology."},{"issue":"10","key":"2026092211273527900_CIT0302","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"2026092211273527900_CIT0303","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"issue":"14","key":"2026092211273527900_CIT0304","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"2026092211273527900_CIT0305","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med."},{"issue":"7","key":"2026092211273527900_CIT0306","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/neuonc\/noae063","article-title":"Locoregional delivery of chimeric antigen receptor-T cells: Breaking the spell in glioblastoma","volume":"26","author":"Geurts","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0307","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40478-020-00980-z","article-title":"Molecular and clinicopathologic features of gliomas harboring NTRK fusions","volume":"8","author":"Torre","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2026092211273527900_CIT0308","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"2026092211273527900_CIT0309","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"2026092211273527900_CIT0310","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/neuonc\/noab080","article-title":"Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult","volume":"23","author":"Boyer","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6","key":"2026092211273527900_CIT0311","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","article-title":"Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma","volume":"119","author":"Ziegler","year":"2018","journal-title":"Br J Cancer."},{"issue":"7-8","key":"2026092211273527900_CIT0312","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000524399","article-title":"Larotrectinib response in NTRK3 fusion-driven diffuse high-grade glioma","volume":"107","author":"Konig","year":"2022","journal-title":"Pharmacology."},{"issue":"3","key":"2026092211273527900_CIT0313","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1078-0432.CCR-24-0581","article-title":"Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions","volume":"31","author":"Lamoureux","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"23","key":"2026092211273527900_CIT0314","doi-asserted-by":"crossref","first-page":"e2086","DOI":"10.1212\/WNL.0000000000005658","article-title":"FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas","volume":"90","author":"Picca","year":"2018","journal-title":"Neurology."},{"issue":"14","key":"2026092211273527900_CIT0315","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2026092211273527900_CIT0316","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","article-title":"Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026092211273527900_CIT0317","first-page":"vdae068","article-title":"TARGET: a phase I\/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed\/refractory FGFR fusion-positive glioma","volume":"6","author":"Picca","year":"2024","journal-title":"Neurooncol. Adv."},{"issue":"35","key":"2026092211273527900_CIT0318","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET Study","volume":"36","author":"Kaley","year":"2018","journal-title":"J Clin Oncol."},{"issue":"10","key":"2026092211273527900_CIT0319","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-23-3241","article-title":"Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma","volume":"30","author":"Schreck","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2026092211273527900_CIT0320","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/neuonc\/noab247","article-title":"Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review","volume":"24","author":"Andrews","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0321","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-023-00359-y","article-title":"Integrated molecular and clinical analysis of BRAF-mutant glioma in adults","volume":"7","author":"Schreck","year":"2023","journal-title":"npj Precis Oncol."},{"issue":"3","key":"2026092211273527900_CIT0322","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jcpt.12378","article-title":"Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma","volume":"41","author":"Ameratunga","year":"2016","journal-title":"J Clin Pharm Ther."},{"issue":"1","key":"2026092211273527900_CIT0323","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"Supplement_5","key":"2026092211273527900_CIT0324","doi-asserted-by":"crossref","first-page":"v97","DOI":"10.1093\/neuonc\/noad179.0366","article-title":"CTNI-85. GBM Agile platform trial for newly diagnosed and recurrent GBM: results of first experimental arm, regorafenib","volume":"25","author":"Wen","year":"2023","journal-title":"Neuro-Oncology."},{"issue":"16_suppl","key":"2026092211273527900_CIT0325","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2024.42.16_suppl.2000","article-title":"N2M2\/NOA-20: Phase I\/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation","volume":"42","author":"Wick","year":"2024","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026092211273527900_CIT0326","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med."},{"issue":"5","key":"2026092211273527900_CIT0327","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol"},{"issue":"9","key":"2026092211273527900_CIT0328","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial","volume":"37","author":"Wen","year":"2019","journal-title":"J Clin Oncol."},{"issue":"Supplement_8","key":"2026092211273527900_CIT0329","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/neuonc\/noae165.1302","article-title":"LTBK-02. Evaluation of Paxalisib in GBM AGILE Phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma","volume":"26","author":"Mellinghoff","year":"2024","journal-title":"Neuro-Oncology."},{"issue":"8","key":"2026092211273527900_CIT0330","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"7","key":"2026092211273527900_CIT0331","doi-asserted-by":"crossref","first-page":"e002459","DOI":"10.1136\/jitc-2021-002459","article-title":"Systematic review of combinations of targeted or immunotherapy in advanced solid tumors","volume":"9","author":"Tan","year":"2021","journal-title":"J ImmunoTher Cancer."},{"issue":"4","key":"2026092211273527900_CIT0332","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1158\/1078-0432.CCR-21-2681","article-title":"Designing clinical trials for combination immunotherapy: a framework for glioblastoma","volume":"28","author":"Singh","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2026092211273527900_CIT0333","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/neuonc\/not247","article-title":"Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02","volume":"16","author":"Wen","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0334","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI89587","article-title":"Overcoming therapeutic resistance in glioblastoma: the way forward","volume":"127","author":"Osuka","year":"2017","journal-title":"J Clin Invest."},{"issue":"9","key":"2026092211273527900_CIT0335","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026092211273527900_CIT0336","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1078-0432.CCR-21-2225","article-title":"A Phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"36","key":"2026092211273527900_CIT0337","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.23.00493","article-title":"Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using Bayesian adaptive randomization","volume":"41","author":"Rahman","year":"2023","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026092211273527900_CIT0338","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3171\/2016.3.JNS152693","article-title":"Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme","volume":"126","author":"Gainer","year":"2017","journal-title":"J Neurosurg."},{"issue":"3","key":"2026092211273527900_CIT0339","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","article-title":"Integrated proteogenomic characterization of glioblastoma evolution","volume":"42","author":"Kim","year":"2024","journal-title":"Cancer Cell"},{"issue":"10","key":"2026092211273527900_CIT0340","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/biom13101499","article-title":"Revisiting concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma-proteomic alteration and comparison analysis with the standard-of-care chemoirradiation","volume":"13","author":"Krauze","year":"2023","journal-title":"Biomolecules"},{"issue":"4","key":"2026092211273527900_CIT0341","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol"},{"issue":"6605","key":"2026092211273527900_CIT0342","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1126\/science.abn7570","article-title":"Mechanism-based design of agents that selectively target drug-resistant glioma","volume":"377","author":"Lin","year":"2022","journal-title":"Science."},{"issue":"3","key":"2026092211273527900_CIT0343","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/neuonc\/noae257","article-title":"The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma","volume":"27","author":"McCord","year":"2024","journal-title":"Neuro Oncol"},{"issue":"16_suppl","key":"2026092211273527900_CIT0344","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.2024.42.16_suppl.2005","article-title":"Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma","volume":"42","author":"de Groot","year":"2024","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026092211273527900_CIT0345","first-page":"vdab015","article-title":"The promise of DNA damage response inhibitors for the treatment of glioblastoma","volume":"3","author":"Majd","year":"2021","journal-title":"Neurooncol. Adv.."},{"issue":"8","key":"2026092211273527900_CIT0346","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/neuonc\/noae072","article-title":"DNA damage response in brain tumors: a society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology","volume":"26","author":"Rahman","year":"2024","journal-title":"Neuro Oncol"},{"issue":"7120","key":"2026092211273527900_CIT0347","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature."},{"issue":"17","key":"2026092211273527900_CIT0348","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-18-0569","article-title":"Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells","volume":"78","author":"Carruthers","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"2026092211273527900_CIT0349","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"8","key":"2026092211273527900_CIT0350","first-page":"12","article-title":"PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status","volume":"8","author":"Fulton","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"2026092211273527900_CIT0351","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2024.01.011","article-title":"Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: the phase 1 dose-escalation PARADIGM trial","volume":"118","author":"Derby","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"2026092211273527900_CIT0352","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","article-title":"A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study","volume":"23","author":"Sim","year":"2021","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026092211273527900_CIT0353","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","article-title":"Efficacy of adding veliparib to temozolomide for patients with MGMT-methylated glioblastoma: a randomized clinical trial","volume":"10","author":"Sarkaria","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026092211273527900_CIT0354","doi-asserted-by":"crossref","first-page":"Abstract 2002","DOI":"10.1200\/JCO.2024.42.16_suppl.2002","article-title":"Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0\/2 \u201ctrigger\u201d trial","volume":"42","author":"Sanai","year":"2024","journal-title":"J Clin Oncol."},{"issue":"7","key":"2026092211273527900_CIT0355","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood-brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"12_Supplement","key":"2026092211273527900_CIT0356","doi-asserted-by":"crossref","first-page":"LB_A12","DOI":"10.1158\/1535-7163.TARG-23-LB_A12","article-title":"Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor","volume":"22","author":"Geurts","year":"2023","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"2026092211273527900_CIT0357","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","article-title":"Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma","volume":"120","author":"Yang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"2026092211273527900_CIT0358","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors","volume":"79","author":"Jackson","year":"2019","journal-title":"Cancer Res."},{"key":"2026092211273527900_CIT0359","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fonc.2018.00670","article-title":"PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity","volume":"8","author":"Gupta","year":"2018","journal-title":"Front Oncol."},{"issue":"14","key":"2026092211273527900_CIT0360","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1158\/1078-0432.CCR-13-3446","article-title":"Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts","volume":"20","author":"Gupta","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2026092211273527900_CIT0361","doi-asserted-by":"crossref","first-page":"djv369","DOI":"10.1093\/jnci\/djv369","article-title":"Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma","volume":"108","author":"Gupta","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"2026092211273527900_CIT0362","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/d41573-024-00080-w","article-title":"WRN inhibitors squeeze cancer cell vulnerability","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov."},{"issue":"8011","key":"2026092211273527900_CIT0363","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","article-title":"Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers","volume":"629","author":"Ferretti","year":"2024","journal-title":"Nature."},{"issue":"12","key":"2026092211273527900_CIT0364","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s12149-022-01806-9","article-title":"Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics","volume":"36","author":"Hertz","year":"2022","journal-title":"Ann Nucl Med."},{"issue":"4","key":"2026092211273527900_CIT0365","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41591-022-01759-6","article-title":"Theranostics could be big business in precision oncology","volume":"28","author":"Arnold","year":"2022","journal-title":"Nat Med."},{"issue":"9","key":"2026092211273527900_CIT0366","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"Supplement_9","key":"2026092211273527900_CIT0367","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1093\/neuonc\/noae125","article-title":"Targeted radionuclide therapy for gliomas: emerging clinical trial landscape","volume":"26","author":"Weller","year":"2024","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0368","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2967\/jnumed.123.266205","article-title":"Theranostics in neurooncology: heading toward new horizons","volume":"65","author":"Tolboom","year":"2024","journal-title":"J Nucl Med."},{"issue":"Supplement_9","key":"2026092211273527900_CIT0369","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1093\/neuonc\/noae191","article-title":"Theranostics and molecular imaging in neuro-oncology: the beginning of a new era","volume":"26","author":"Albert","year":"2024","journal-title":"Neuro Oncol."},{"issue":"12","key":"2026092211273527900_CIT0370","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2967\/jnumed.122.264321","article-title":"Joint EANM, SNMMI, and IAEA enabling guide: how to set up a theranostics center","volume":"63","author":"Herrmann","year":"2022","journal-title":"J Nucl Med."},{"issue":"Supplement_9","key":"2026092211273527900_CIT0371","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/neuonc\/noae162","article-title":"Design and conduct of theranostic trials in neuro-oncology: challenges and opportunities","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro Oncol."},{"issue":"3","key":"2026092211273527900_CIT0372","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"issue":"9","key":"2026092211273527900_CIT0373","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med."},{"issue":"6","key":"2026092211273527900_CIT0374","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"2026092211273527900_CIT0375","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026092211273527900_CIT0376","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/neuonc\/noad205","article-title":"Systematic characterization of antibody-drug conjugate targets in central nervous system tumors","volume":"26","author":"Coy","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026092211273527900_CIT0377","doi-asserted-by":"crossref","first-page":"117657","DOI":"10.1016\/j.bmc.2024.117657","article-title":"AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy","volume":"102","author":"Li","year":"2024","journal-title":"Bioorg Med Chem."},{"key":"2026092211273527900_CIT0378","doi-asserted-by":"crossref","first-page":"100982","DOI":"10.1016\/j.neo.2024.100982","article-title":"Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma","volume":"50","author":"Uchida","year":"2024","journal-title":"Neoplasia"},{"key":"2026092211273527900_CIT0379","doi-asserted-by":"crossref","first-page":"115489","DOI":"10.1016\/j.ejmech.2023.115489","article-title":"Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma","volume":"257","author":"Mao","year":"2023","journal-title":"Eur J Med Chem."},{"issue":"8","key":"2026092211273527900_CIT0380","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/1878-0261.13453","article-title":"Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma","volume":"17","author":"Dufrusine","year":"2023","journal-title":"Mol Oncol."},{"issue":"7","key":"2026092211273527900_CIT0381","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/ph15070837","article-title":"Identification of CD73 as the antigen of an antigen-unknown monoclonal antibody established by exosome immunization, and its antibody-drug conjugate exerts an antitumor effect on glioblastoma cell lines","volume":"15","author":"Anzai","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"2026092211273527900_CIT0382","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14712598.2023.2282729","article-title":"Antibody drug conjugates for glioblastoma: current progress towards clinical use","volume":"23","author":"Gan","year":"2023","journal-title":"Expert Opin Biol Ther."},{"issue":"1","key":"2026092211273527900_CIT0383","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12885-024-11846-1","article-title":"PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma","volume":"24","author":"Heuer","year":"2024","journal-title":"BMC Cancer"},{"issue":"23","key":"2026092211273527900_CIT0384","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-24-1849","article-title":"Pilot trial of perampanel on peritumoral hyperexcitability in newly diagnosed high-grade glioma","volume":"30","author":"Tobochnik","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2026092211273527900_CIT0385","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm.2453","article-title":"Glutamate release by primary brain tumors induces epileptic activity","volume":"17","author":"Buckingham","year":"2011","journal-title":"Nat Med."},{"issue":"4","key":"2026092211273527900_CIT0386","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2016.26","article-title":"Seizures and gliomas--towards a single therapeutic approach","volume":"12","author":"Huberfeld","year":"2016","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"2026092211273527900_CIT0387","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12885-023-11797-z","article-title":"A phase Ib\/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol","volume":"24","author":"Mastall","year":"2024","journal-title":"BMC Cancer"},{"issue":"11","key":"2026092211273527900_CIT0388","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41591-024-03224-y","article-title":"High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity","volume":"30","author":"Lee","year":"2024","journal-title":"Nat Med."},{"issue":"11","key":"2026092211273527900_CIT0389","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/neuonc\/noab092","article-title":"Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma","volume":"23","author":"Schneider","year":"2021","journal-title":"Neuro Oncol"},{"issue":"26","key":"2026092211273527900_CIT0390","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"issue":"7","key":"2026092211273527900_CIT0391","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"9","key":"2026092211273527900_CIT0392","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat Immunol."},{"issue":"12","key":"2026092211273527900_CIT0393","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov."},{"issue":"6731","key":"2026092211273527900_CIT0394","doi-asserted-by":"crossref","first-page":"eabm5214","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science."},{"issue":"9","key":"2026092211273527900_CIT0395","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ccell.2024.08.008","article-title":"Glioblastoma induces the recruitment and differentiation of hybrid neutrophils from skull bone marrow","volume":"42","author":"Lad","year":"2024","journal-title":"Cancer Cell"},{"issue":"16","key":"2026092211273527900_CIT0396","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"370","key":"2026092211273527900_CIT0397","doi-asserted-by":"crossref","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci Transl Med."},{"issue":"15","key":"2026092211273527900_CIT0398","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell."},{"issue":"12","key":"2026092211273527900_CIT0399","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene."},{"issue":"7","key":"2026092211273527900_CIT0400","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol."},{"issue":"7738","key":"2026092211273527900_CIT0401","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature."},{"issue":"7738","key":"2026092211273527900_CIT0402","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature."},{"issue":"1","key":"2026092211273527900_CIT0403","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"2026092211273527900_CIT0404","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/neuonc\/noac281","article-title":"Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana","volume":"25","author":"Preusser","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026092211273527900_CIT0405","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/neuonc\/noad088","article-title":"Dendritic cell vaccine trials in gliomas: Untangling the lines","volume":"25","author":"Hotchkiss","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026092211273527900_CIT0406","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-023-01776-0","article-title":"Molecular mimicry and cancer vaccine development","volume":"22","author":"Tagliamonte","year":"2023","journal-title":"Mol Cancer."},{"issue":"2","key":"2026092211273527900_CIT0407","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/neuonc\/noae203","article-title":"Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations","volume":"27","author":"Gallus","year":"2025","journal-title":"Neuro Oncol"},{"issue":"9","key":"2026092211273527900_CIT0408","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med."},{"issue":"26","key":"2026092211273527900_CIT0409","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2026092211273527900_CIT0410","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med."},{"issue":"9","key":"2026092211273527900_CIT0411","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol."},{"issue":"3","key":"2026092211273527900_CIT0412","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"issue":"4","key":"2026092211273527900_CIT0413","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov."},{"issue":"9","key":"2026092211273527900_CIT0414","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.3390\/curroncol30090619","article-title":"Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update","volume":"30","author":"Alsajjan","year":"2023","journal-title":"Curr Oncol"},{"key":"2026092211273527900_CIT0415","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","article-title":"Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation","volume":"52","author":"Murer","year":"2019","journal-title":"N Biotechnol"},{"issue":"19","key":"2026092211273527900_CIT0416","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-22-1837","article-title":"Facts and hopes: immunocytokines for cancer immunotherapy","volume":"29","author":"Pabani","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"564","key":"2026092211273527900_CIT0417","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci Transl Med."},{"issue":"697","key":"2026092211273527900_CIT0418","doi-asserted-by":"crossref","first-page":"eadf2281","DOI":"10.1126\/scitranslmed.adf2281","article-title":"Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma","volume":"15","author":"Look","year":"2023","journal-title":"Sci Transl Med."},{"issue":"2","key":"2026092211273527900_CIT0419","doi-asserted-by":"crossref","first-page":"e163452","DOI":"10.1172\/JCI163452","article-title":"Understanding and therapeutically exploiting cGAS\/STING signaling in glioblastoma","volume":"134","author":"Low","year":"2024","journal-title":"J Clin Invest."},{"issue":"4","key":"2026092211273527900_CIT0420","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized Phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2026092211273527900_CIT0421","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/1078-0432.CCR-24-1629","article-title":"Re-irradiation plus pembrolizumab: a phase II study for patients with recurrent glioblastoma","volume":"31","author":"Iwamoto","year":"2025","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2026092211273527900_CIT0422","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med."},{"issue":"1","key":"2026092211273527900_CIT0423","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun."},{"issue":"1","key":"2026092211273527900_CIT0424","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1038\/s41467-023-43201-6","article-title":"High-sensitive spatially resolved T cell receptor sequencing with SPTCR-seq","volume":"14","author":"Benotmane","year":"2023","journal-title":"Nat Commun."},{"issue":"1","key":"2026092211273527900_CIT0425","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s42466-022-00184-x","article-title":"AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas","volume":"4","author":"Bunse","year":"2022","journal-title":"Neurol Res Pract"},{"issue":"1","key":"2026092211273527900_CIT0426","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun."},{"issue":"6","key":"2026092211273527900_CIT0427","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s13311-022-01256-1","article-title":"Oncolytic viral therapy for malignant glioma and their application in clinical practice","volume":"19","author":"Shoaf","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"8","key":"2026092211273527900_CIT0428","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2026092211273527900_CIT0429","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2020.11.FOCUS20844","article-title":"Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas","volume":"50","author":"Omar","year":"2021","journal-title":"Neurosurg Focus."},{"issue":"3","key":"2026092211273527900_CIT0430","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-21-2636","article-title":"Immune activity and response differences of oncolytic viral therapy in recurrent glioblastoma: gene expression analyses of a phase IB Study","volume":"28","author":"Miller","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"26","key":"2026092211273527900_CIT0431","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Gallego Perez-Larraya","year":"2022","journal-title":"N Engl J Med."},{"issue":"8","key":"2026092211273527900_CIT0432","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026092211273527900_CIT0433","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med."},{"issue":"1","key":"2026092211273527900_CIT0434","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat Commun."},{"issue":"8","key":"2026092211273527900_CIT0435","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med."},{"issue":"1","key":"2026092211273527900_CIT0436","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun."},{"issue":"9","key":"2026092211273527900_CIT0437","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol."},{"issue":"7985","key":"2026092211273527900_CIT0438","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature."},{"issue":"6","key":"2026092211273527900_CIT0439","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro Oncol"},{"issue":"505","key":"2026092211273527900_CIT0440","doi-asserted-by":"crossref","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med."},{"issue":"1","key":"2026092211273527900_CIT0441","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/noy170","article-title":"Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual","volume":"21","author":"Chiocca","year":"2019","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026092211273527900_CIT0442","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41591-018-0142-3","article-title":"Immunotherapy for glioblastoma: going viral","volume":"24","author":"Iorgulescu","year":"2018","journal-title":"Nat Med."},{"issue":"8","key":"2026092211273527900_CIT0443","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro Oncol"},{"issue":"12","key":"2026092211273527900_CIT0444","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol"},{"issue":"14","key":"2026092211273527900_CIT0445","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol."},{"issue":"2","key":"2026092211273527900_CIT0446","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med."},{"key":"2026092211273527900_CIT0447","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","author":"Wen","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"10","key":"2026092211273527900_CIT0448","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/s41591-023-02464-8","article-title":"Correcting the drug development paradigm for glioblastoma requires serial tissue sampling","volume":"29","author":"Singh","year":"2023","journal-title":"Nat Med."},{"issue":"2","key":"2026092211273527900_CIT0449","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/neuonc\/noad211","article-title":"Lessons learned from phase 3 trials of immunotherapy for glioblastoma: time for longitudinal sampling","volume":"26","author":"Chen","year":"2024","journal-title":"Neuro Oncol."},{"issue":"13","key":"2026092211273527900_CIT0450","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-18-3643","article-title":"Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma","volume":"25","author":"Idbaih","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2026092211273527900_CIT0451","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","article-title":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","volume":"24","author":"Sonabend","year":"2023","journal-title":"Lancet Oncol."},{"issue":"615","key":"2026092211273527900_CIT0452","doi-asserted-by":"crossref","first-page":"eabj4011","DOI":"10.1126\/scitranslmed.abj4011","article-title":"MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases","volume":"13","author":"Meng","year":"2021","journal-title":"Sci Transl Med."},{"issue":"1","key":"2026092211273527900_CIT0453","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yao.2023.01.017","article-title":"Advances in blood-brain barrier disruption to facilitate drug delivery for infiltrative gliomas","volume":"3","author":"Gould","year":"2023","journal-title":"Adv Oncol."},{"issue":"2","key":"2026092211273527900_CIT0454","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J Neurooncol."},{"issue":"1","key":"2026092211273527900_CIT0455","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-021-03837-0","article-title":"Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients","volume":"156","author":"Rincon-Torroella","year":"2022","journal-title":"J Neurooncol."},{"issue":"3","key":"2026092211273527900_CIT0456","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/2024.6.FOCUS24338","article-title":"A review of sonodynamic therapy for brain tumors","volume":"57","author":"Hutton","year":"2024","journal-title":"Neurosurg Focus."},{"issue":"4","key":"2026092211273527900_CIT0457","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(23)00005-0","article-title":"Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference","volume":"24","author":"Rahman","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026092211273527900_CIT0458","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/neuonc\/noac226","article-title":"Negative trials over and over again: How can we do better","volume":"25","author":"McFaline-Figueroa","year":"2023","journal-title":"Neuro Oncol"},{"issue":"30","key":"2026092211273527900_CIT0459","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.21.02166","article-title":"Balancing risk and efficiency in drug development for rare and challenging tumors: a new paradigm for glioma","volume":"40","author":"Mellinghoff","year":"2022","journal-title":"J Clin Oncol."},{"issue":"6","key":"2026092211273527900_CIT0460","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/neuonc\/noac263","article-title":"Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, \u201cwindow-of-opportunity\u201d study","volume":"25","author":"Moreno","year":"2023","journal-title":"Neuro Oncol"},{"issue":"19","key":"2026092211273527900_CIT0461","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","article-title":"A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- and pharmacokinetic-guided expansion cohort","volume":"25","author":"Tien","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2026092211273527900_CIT0462","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","article-title":"Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review","volume":"22","author":"Vogelbaum","year":"2020","journal-title":"Neuro Oncol"},{"issue":"786","key":"2026092211273527900_CIT0463","doi-asserted-by":"crossref","first-page":"eadn6274","DOI":"10.1126\/scitranslmed.adn6274","article-title":"A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma","volume":"17","author":"Rendo","year":"2025","journal-title":"Sci Transl Med."},{"issue":"30","key":"2026092211273527900_CIT0464","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Fourie Zirkelbach","year":"2022","journal-title":"J Clin Oncol."},{"issue":"8","key":"2026092211273527900_CIT0465","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The clinical trials landscape for glioblastoma: is it adequate to develop new treatments","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026092211273527900_CIT0466","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/neuonc\/nox030","article-title":"Point\/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma","volume":"19","author":"Grossman","year":"2017","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026092211273527900_CIT0467","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/neuonc\/noz097","article-title":"To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs","volume":"21","author":"Vanderbeek","year":"2019","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026092211273527900_CIT0468","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2026092211273527900_CIT0469","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S1470-2045(21)00488-5","article-title":"Leveraging external data in the design and analysis of clinical trials in neuro-oncology","volume":"22","author":"Rahman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"2026092211273527900_CIT0470","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1038\/s41467-022-33192-1","article-title":"The design and evaluation of hybrid controlled trials that leverage external data and randomization","volume":"13","author":"Ventz","year":"2022","journal-title":"Nat Commun."},{"issue":"12","key":"2026092211273527900_CIT0471","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-22-3524","article-title":"Accessible data collections for improved decision making in neuro-oncology clinical trials","volume":"29","author":"Rahman","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026092211273527900_CIT0472","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/noy161","article-title":"N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma","volume":"21","author":"Wick","year":"2019","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026092211273527900_CIT0473","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-022-00475-0","article-title":"Disconnecting multicellular networks in brain tumours","volume":"22","author":"Venkataramani","year":"2022","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"2026092211273527900_CIT0474","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuonc\/nov013","article-title":"Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas","volume":"17","author":"van den Bent","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026092211273527900_CIT0475","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"712","key":"2026092211273527900_CIT0476","doi-asserted-by":"crossref","first-page":"eadi0069","DOI":"10.1126\/scitranslmed.adi0069","article-title":"Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas","volume":"15","author":"Peruzzi","year":"2023","journal-title":"Sci Transl Med."},{"issue":"6","key":"2026092211273527900_CIT0477","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noac004","article-title":"Liquid biopsy in gliomas: a RANO review and proposals for clinical applications","volume":"24","author":"Soffietti","year":"2022","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf177\/64081192\/noaf177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/11\/2751\/64081192\/noaf177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/11\/2751\/64081192\/noaf177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:29:02Z","timestamp":1790090942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/11\/2751\/8237727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":477,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,8,13]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf177","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,13]]}}}